Medical Properties Trust, Inc. (MPT)
NYSE: MPT · Real-Time Price · USD
5.49
-0.16 (-2.83%)
Mar 3, 2026, 12:18 PM EST - Market open

Medical Properties Trust Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Medical Properties Trust stock has a target of 5.00, which predicts a -8.93% decrease from the current stock price of 5.49.

Price Target: $5.00 (-8.93%)
Analyst Consensus: Hold
TargetLowAverageMedianHigh
Price$5.00$5.00$5.00$5.00
Change-8.93%-8.93%-8.93%-8.93%

Analyst Ratings

According to 1 stock analyst, the rating for Medical Properties Trust is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

RatingMar '26
Strong Buy0
Buy0
Hold1
Sell0
Strong Sell0
Total1

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
RBC Capital
RBC Capital
Hold
Maintains
$4.5$5
HoldMaintains$4.5$5-8.93%Mar 2, 2026

Financial Forecast

Revenue This Year
1.01B
from 1.07B
Decreased by -5.69%
Revenue Next Year
1.08B
from 1.01B
Increased by 7.14%
EPS This Year
0.09
from -0.46
EPS Next Year
0.16
from 0.09
Increased by 71.20%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
1.57B1.58B885.77M1.04B1.07B1.01B1.08B
Revenue Growth
23.90%0.67%-44.07%17.38%2.90%-5.69%7.14%
EPS
1.111.50-0.93-4.02-0.460.090.16
EPS Growth
37.04%35.14%----71.20%
Forward PE
-----59.0834.51
No. Analysts
-----65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027202820292030
High1.1B1.2B
Avg1.0B1.1B
Low913.8M1.0B

Revenue Growth

Revenue Growth20262027202820292030
High
2.3%
15.9%
Avg
-5.7%
7.1%
Low
-14.6%
-0.2%

EPS Forecast

EPS20262027
High0.150.23
Avg0.090.16
Low0.050.12

EPS Growth

EPS Growth20262027
High-
148.6%
Avg-
71.2%
Low-
26.6%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.